178 related articles for article (PubMed ID: 25284004)
1. Dovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder.
Mazzola CR; Siddiqui KM; Billia M; Chin J
Expert Opin Investig Drugs; 2014 Nov; 23(11):1553-62. PubMed ID: 25284004
[TBL] [Abstract][Full Text] [Related]
2. A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with
Hahn NM; Bivalacqua TJ; Ross AE; Netto GJ; Baras A; Park JC; Chapman C; Masterson TA; Koch MO; Bihrle R; Foster RS; Gardner TA; Cheng L; Jones DR; McElyea K; Sandusky GE; Breen T; Liu Z; Albany C; Moore ML; Loman RL; Reed A; Turner SA; De Abreu FB; Gallagher T; Tsongalis GJ; Plimack ER; Greenberg RE; Geynisman DM
Clin Cancer Res; 2017 Jun; 23(12):3003-3011. PubMed ID: 27932416
[No Abstract] [Full Text] [Related]
3. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma.
Milowsky MI; Dittrich C; Durán I; Jagdev S; Millard FE; Sweeney CJ; Bajorin D; Cerbone L; Quinn DI; Stadler WM; Rosenberg JE; Lochheed M; Sen P; Squires M; Shi M; Sternberg CN
Eur J Cancer; 2014 Dec; 50(18):3145-52. PubMed ID: 25457633
[TBL] [Abstract][Full Text] [Related]
5. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapies in bladder cancer--an update.
Black PC; Agarwal PK; Dinney CP
Urol Oncol; 2007; 25(5):433-8. PubMed ID: 17826665
[TBL] [Abstract][Full Text] [Related]
7. Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer.
Dodurga Y; Tataroglu C; Kesen Z; Satiroglu-Tufan NL
Genet Mol Res; 2011 Jan; 10(1):86-95. PubMed ID: 21264819
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor receptor-3 in urothelial tumorigenesis.
Iyer G; Milowsky MI
Urol Oncol; 2013 Apr; 31(3):303-11. PubMed ID: 22285006
[TBL] [Abstract][Full Text] [Related]
9. MMP-1 and Pro-MMP-10 as potential urinary pharmacodynamic biomarkers of FGFR3-targeted therapy in patients with bladder cancer.
Du X; Lin BC; Wang QR; Li H; Ingalla E; Tien J; Rooney I; Ashkenazi A; Penuel E; Qing J
Clin Cancer Res; 2014 Dec; 20(24):6324-35. PubMed ID: 25326231
[TBL] [Abstract][Full Text] [Related]
10. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.
Lamont FR; Tomlinson DC; Cooper PA; Shnyder SD; Chester JD; Knowles MA
Br J Cancer; 2011 Jan; 104(1):75-82. PubMed ID: 21119661
[TBL] [Abstract][Full Text] [Related]
11. Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer.
Escudier B; Grünwald V; Ravaud A; Ou YC; Castellano D; Lin CC; Gschwend JE; Harzstark A; Beall S; Pirotta N; Squires M; Shi M; Angevin E
Clin Cancer Res; 2014 Jun; 20(11):3012-22. PubMed ID: 24691021
[TBL] [Abstract][Full Text] [Related]
12. Frequent FGFR3 mutations in urothelial papilloma.
van Rhijn BW; Montironi R; Zwarthoff EC; Jöbsis AC; van der Kwast TH
J Pathol; 2002 Oct; 198(2):245-51. PubMed ID: 12237885
[TBL] [Abstract][Full Text] [Related]
13. Editorial comment on: Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study.
Montironi R; Lopez-Beltran A; Cheng L
Eur Urol; 2008 Oct; 54(4):843-4. PubMed ID: 18166261
[No Abstract] [Full Text] [Related]
14. Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification.
Palma N; Morris JC; Ali SM; Ross JS; Pal SK
Eur Urol; 2015 Jul; 68(1):168-70. PubMed ID: 25766722
[No Abstract] [Full Text] [Related]
15. Targeting Signaling Transduction Pathways in Bladder Cancer.
Abbosh PH; McConkey DJ; Plimack ER
Curr Oncol Rep; 2015 Dec; 17(12):58. PubMed ID: 26472299
[TBL] [Abstract][Full Text] [Related]
16. FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation.
Azab AK; Azab F; Quang P; Maiso P; Sacco A; Ngo HT; Liu Y; Zhang Y; Morgan BL; Roccaro AM; Ghobrial IM
Clin Cancer Res; 2011 Jul; 17(13):4389-99. PubMed ID: 21521775
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast growth factor receptors across urothelial carcinoma landscape.
Ertl IE; Shariat SF; Mostafaei H; Ilijazi D; Loriot Y
Curr Opin Urol; 2020 Jul; 30(4):557-565. PubMed ID: 32452999
[TBL] [Abstract][Full Text] [Related]
18. Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors.
Knowles MA
Future Oncol; 2008 Feb; 4(1):71-83. PubMed ID: 18241002
[TBL] [Abstract][Full Text] [Related]
19. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.
Jebar AH; Hurst CD; Tomlinson DC; Johnston C; Taylor CF; Knowles MA
Oncogene; 2005 Aug; 24(33):5218-25. PubMed ID: 15897885
[TBL] [Abstract][Full Text] [Related]
20. FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy.
Sung JY; Sun JM; Chang Jeong B; Il Seo S; Soo Jeon S; Moo Lee H; Yong Choi H; Young Kang S; Choi YL; Young Kwon G
Urol Oncol; 2014 Jan; 32(1):49.e23-31. PubMed ID: 24360661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]